Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Delcath Systems Inc
DCTHCurrent price
11.63 USD
+0.08 USD (+0.69%)
Last closed
10.91 USD
Company
www.delcath.com
ISIN
US24661P8077
Sector
Healthcare
Industry
Medical Devices
Exchange
NASDAQ
Capitalization
388 821 152 USD
Yield for 12 month
+111.07 %
1Y
3Y
5Y
10Y
15Y
DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York. Address: 566 Queensbury Avenue, New York, NY, United States, 12804
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
22.50 USDP/E ratio
–Dividend Yield
–Current Year
+31 017 000 USD
Last Year
+2 065 000 USD
Current Quarter
+15 100 000 USD
Last Quarter
+9 560 000 USD
Current Year
+31 017 000 USD
Last Year
+1 430 000 USD
Current Quarter
+12 974 000 USD
Last Quarter
+9 560 000 USD
Key Figures DCTH
1 year
3 years
5 years
10 years
EBITDA
-12 276 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-13.47 %
PEG Ratio
–
Return On Equity TTM
-58.59 %
Wall Street Target Price
22.50 USD
Revenue TTM
37 205 000 USD
Book Value
2.08 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
2 701.50 %
Dividend Yield
–
Gross Profit TTM
31 017 000 USD
Earnings per share
-0.93 USD
Diluted Eps TTM
-0.93 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-70.92 %
Dividend Analytics DCTH
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History DCTH
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:700
Payout Ratio
–
Last Split Date
24.12.2019
Stock Valuation DCTH
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
97.09
Enterprise Value Revenue
9.05
Price Sales TTM
10.45
Enterprise Value EBITDA
-1.92
Price Book MRQ
5.66
Financials DCTH
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators DCTH
For 52 weeks
4.87 USD
16.97 USD
50 Day MA
13.43 USD
Shares Short Prior Month
805 251
200 Day MA
11.11 USD
Short Ratio
1.79
Shares Short
861 829
Short Percent
2.62 %
BeatStart